http://www.raredr.com/news/len-walt-nomid
Len Walt of Sobi in North America Explains NOMID

Len Walt



Len Walt has been employed at Sobi in North America since 2015, first in a stint as the Medical Director of Canada. From 2015-2016, he served as the company’s Global Medical Director and has since been named the Vice President and Head of Medical Affairs. He has held a variety of Medical Affairs roles and boasts more than 25 years of experience in the biotechnology and pharmaceutical industries.

In this video, he discusses neonatal-onset multisystem inflammatory disease (NOMID), the umbrella disease under which it resides, symptoms of the condition, and why it’s so difficult to diagnose.

Walt: Let’s start off with what NOMID stands for: it’s neonatal-onset multisystem inflammatory disease, which really tells you what this disease is all about. NOMID is part of an umbrella term known as CAPS, which is cryoporin-associated periodic syndrome. (NOMID) is the most severe form of CAPS – the first (least severe) being FCAS (familial cold autoinflammatory syndrome), the second being Muckle-Wells, and the third (most severe) being NOMID. Once again, NOMID is a rare genetic condition that is due to a genetic defect, or a mutation in a specific gene, and as a result of that, it produces very high levels of interleukin-1, or IL1. IL1 is a pro-inflammatory cytokine, and what IL1 does is it increases inflammation throughout the body. What patients typically present with are fever, skin rashes, and arthritis, and then the inflammation can spread to key organs like the brain, the lungs, and the heart. It really can affect all organs in the body at a very young age in these patients.

Once again, these patients often present in their early lives, and they can present in a number of different ways. Sometimes, it’s not that easy to diagnose these patients. They’ll come in with very non-specific symptoms, like a fever, rash, or arthritis. That’s why it is quite challenging for a physician to move through the differential diagnosis to arrive at the diagnosis of NOMID. Very often, this is done through genetic screening, or it’s just managed by physicians that are experts in this rare autoinflammatory disease space.

--

For more from Sobi and other pharmaceutical companies catering to the rare disease community, follow Rare Disease Report on Facebook and Twitter.
Printer Printing...
$content$